Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency
Laura Fabbri(Royal Brompton Hospital), Julien Guiot(University of Liège), Dávid László Tárnoki(Semmelweis University), Helmut Prosch(Medical University of Vienna), Pierre Foidart(Brigham and Women's Hospital), Anne‐Marie Russell(Birmingham City University), Aurélie Cazes(Université Paris Cité), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Solange Peters(University Hospital of Lausanne), Joanna C. Porter(University College Hospital), Joanna Chorostowska‐Wynimko(Unknown), Torsten Blum(MSB Medical School Berlin), Philippe Camus(Inserm), Katerina Antoniou(University of Crete), Marjolein A. Heuvelmans(University Medical Center Groningen), Georgia Hardavella(Sotiria General Hospital), Antonio Passaro(European Institute of Oncology), Maria Joana Catarata(Hospital Braga), Michael Kreuter(Johannes Gutenberg University Mainz), Τheodoros Karampitsakos(University of South Florida)
Cited by 0
Related Papers
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k